Innate Pharma (IPHA) Change in Working Capital (2019 - 2024)
Historic Change in Working Capital for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to $41.8 million.
- Innate Pharma's Change in Working Capital rose 22119.74% to $41.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$85.3 million, marking a year-over-year decrease of 772.47%. This contributed to the annual value of -$41.8 million for FY2024, which is 22119.74% down from last year.
- Latest data reveals that Innate Pharma reported Change in Working Capital of $41.8 million as of Q4 2024, which was up 22119.74% from -$72.4 million recorded in Q2 2024.
- Innate Pharma's 5-year Change in Working Capital high stood at $41.8 million for Q4 2024, and its period low was -$72.4 million during Q2 2024.
- Over the past 5 years, Innate Pharma's median Change in Working Capital value was -$17.7 million (recorded in 2023), while the average stood at -$25.8 million.
- Data for Innate Pharma's Change in Working Capital shows a peak YoY increase of 22119.74% (in 2024) and a maximum YoY decrease of 25897.2% (in 2024) over the last 5 years.
- Quarter analysis of 5 years shows Innate Pharma's Change in Working Capital stood at -$58.7 million in 2020, then skyrocketed by 80.73% to -$11.3 million in 2021, then fell by 12.82% to -$12.8 million in 2022, then tumbled by 170.69% to -$34.5 million in 2023, then surged by 221.2% to $41.8 million in 2024.
- Its Change in Working Capital was $41.8 million in Q4 2024, compared to -$72.4 million in Q2 2024 and -$34.5 million in Q4 2023.